Current Report Filing (8-k)
May 29 2019 - 5:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 23, 2019
CATALYST PHARMACEUTICALS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
|
|
|
|
|
Delaware
|
|
001-33057
|
|
76-0837053
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
355 Alhambra Circle
Suite 1250
Coral Gables,
Florida
|
|
33134
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code: (305)
420-3200
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule
14d-2(b)
under the
Exchange Act (17
CFR240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule
13e-4(c)
under the
Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to
Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Name of Exchange
on Which Registered
|
|
Ticker
Symbol
|
Common Stock, par value $0.001 per share
|
|
NASDAQ Capital Market
|
|
CPRX
|
|
Item 5.02(e)
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
|
At the Companys 2019 Annual Meeting of Stockholders held on
May 23, 2019, Patrick J. McEnany, Philip H. Coelho, Charles B. OKeeffe, David S. Tierney, Richard J. Daly and Donald A. Denkhaus were elected to the Companys Board of Directors to serve until the 2020 Annual Meeting of Stockholders
or until their successor is duly elected and qualified, or until their earlier death, resignation or removal.
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
On May 23, 2019, the Company held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables,
Florida. The final voting results on the matters considered at the meeting are as follows:
1. Election of Directors:
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker Non-Votes
|
|
Patrick J. McEnany
|
|
|
59,876,973
|
|
|
|
225,603
|
|
|
|
34,696,011
|
|
Philip H. Coelho
|
|
|
51,084,450
|
|
|
|
9,018,126
|
|
|
|
34,696,011
|
|
Charles B. OKeeffe
|
|
|
57,871,148
|
|
|
|
2,231,428
|
|
|
|
34,696,011
|
|
David S. Tierney
|
|
|
54,915,453
|
|
|
|
5,187,123
|
|
|
|
34,696,011
|
|
Richard J. Daly
|
|
|
59,712,828
|
|
|
|
389,748
|
|
|
|
34,696,011
|
|
Donald A. Denkhaus
|
|
|
57,885,970
|
|
|
|
2,216,606
|
|
|
|
34,696,011
|
|
2. Approval, on an advisory basis, of the 2018 compensation of the Companys Named Executive Officers:
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
Broker Non-Votes
|
59,643,267
|
|
231,360
|
|
227,949
|
|
34,696,011
|
3. Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of the
Companys Named Executive officers:
|
|
|
|
|
|
|
|
|
Every Year
|
|
Every Two Years
|
|
Every Three Years
|
|
Votes Abstained
|
|
Broker Non-Votes
|
53,941,585
|
|
136,701
|
|
5,716,260
|
|
308,030
|
|
34,696,011
|
4. Ratification of the selection of Grant Thornton, LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2019:
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
92,479,371
|
|
1,919,713
|
|
399,503
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
Catalyst Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Alicia Grande
|
Alicia Grande
|
Vice President, Treasurer and Chief Financial Officer
|
Dated: May 28, 2019
3
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024